Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective inhibition of human 3β-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer.

The Journal of steroid biochemistry and molecular biology - 1 May 2011

Thomas James L, Bucholtz Kevin M, Kacsoh Balint

Abstract excerpt

Human 3β-hydroxysteroid dehydrogenase/isomerase type 1 (3β-HSD1) is a critical enzyme in the conversion of DHEA to estradiol in breast tumors and may be a target enzyme for inhibition in the treatment of breast cancer in postmenopausal women. Human 3β-HSD2 participates in the production of cortisol and aldosterone in the human adrenal gland in this population. In our recombinant human breast tumor MCF-7 Tet-off...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3-Hydroxysteroid Dehydrogenases
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line

Share to Isoenzymes

Share to Models, Molecular

Share to Molecular Structure

Share to Protein Conformation

Share to Steroids

Source

Open in PubMed Open full text

Identifiers

PMID: 20736065
DOI: 10.1016/j.jsbmb.2010.08.003
PMCID: PMC2999670

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective inhibition of human 3β-hydroxysteroid dehydrogenase type 1 as a potential treatment for breast cancer.PMID 20736065Read ↗

Design and validation of specific inhibitors of 17 -hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosisSemantic proximity Read ↗

Identification of key amino acids responsible for the substantially higher affinities of human type 1 3beta-hydroxysteroid dehydrogenase/isomerase (3beta-HSD1) for substrates, coenzymes, and inhibitors relative to human 3beta-HSD2.Semantic proximity Read ↗

Structure/function aspects of human 3beta-hydroxysteroid dehydrogenase.Semantic proximity Read ↗

Current knowledge of the multifunctional 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1).Semantic proximity Read ↗

Small Molecule 11β- Hydroxysteroid Dehydrogenase Type 1 InhibitorsSemantic proximity Read ↗

Molecular basis for the interaction of four different classes of substrates and inhibitors with human aromataseSemantic proximity Read ↗

Evaluation of inhibitors for 17β-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzymeSemantic proximity Read ↗

Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1_937_G variant.Semantic proximity Read ↗

The potential for aromatase inhibition in breast cancer prevention.Semantic proximity Read ↗

Differences in substrate and inhibitor kinetics of human type 1 and type 2 3beta-hydroxysteroid dehydrogenase are explained by the type 1 mutant, H156Y.Semantic proximity Read ↗

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.Semantic proximity Read ↗

Molecular mechanisms of estrogen recognition and 17-keto reduction by human 17beta-hydroxysteroid dehydrogenase 1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.